Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genentech

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

87 comunicati stampa

Guarda tutti i comunicati
11/06/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
02/06/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
Fonte
Genentech
Emittente
Business Wire
1.00
0
01/06/2026
Eventi
Web e Social Network
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Fonte
Genentech
Emittente
Business Wire
1.00
0
19/05/2026
Eventi
Fiere
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
15/05/2026
Industria
Biologia
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Oncologia
Scienza
Medicina - Varie
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
Fonte
Genentech
Emittente
Business Wire
1.00
0
30/04/2026
Eventi
Fiere
Industria
Scienza
Biotecnologia
Farmaceutica
Ottica
Sanità
Salute
Medicina - Varie
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
Fonte
Genentech
Emittente
Business Wire
1.00
0
24/04/2026
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
Fonte
Genentech
Emittente
Business Wire
1.00
0
21/04/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
Fonte
Genentech
Emittente
Business Wire
1.00
0
21/04/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
Fonte
Genentech
Emittente
Business Wire
1.00
0
21/04/2026
Eventi
Fiere
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
CORRECTING and REPLACING FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
Fonte
Genentech
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0